IL156064A0 - Vla-4 inhibitors - Google Patents

Vla-4 inhibitors

Info

Publication number
IL156064A0
IL156064A0 IL15606401A IL15606401A IL156064A0 IL 156064 A0 IL156064 A0 IL 156064A0 IL 15606401 A IL15606401 A IL 15606401A IL 15606401 A IL15606401 A IL 15606401A IL 156064 A0 IL156064 A0 IL 156064A0
Authority
IL
Israel
Prior art keywords
vla
inhibitors
Prior art date
Application number
IL15606401A
Other languages
English (en)
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of IL156064A0 publication Critical patent/IL156064A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15606401A 2000-12-28 2001-12-28 Vla-4 inhibitors IL156064A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000402890 2000-12-28
JP2001149923 2001-05-18
PCT/JP2001/011641 WO2002053534A1 (fr) 2000-12-28 2001-12-28 Inhibiteurs de vla-4

Publications (1)

Publication Number Publication Date
IL156064A0 true IL156064A0 (en) 2003-12-23

Family

ID=26607210

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15606401A IL156064A0 (en) 2000-12-28 2001-12-28 Vla-4 inhibitors

Country Status (17)

Country Link
US (1) US7157487B2 (fr)
EP (1) EP1346982B1 (fr)
JP (1) JP4212358B2 (fr)
KR (1) KR100884877B1 (fr)
CN (1) CN100471838C (fr)
AR (1) AR035218A1 (fr)
AT (1) ATE524441T1 (fr)
AU (1) AU2002219555B2 (fr)
BR (1) BR0116608A (fr)
CA (1) CA2430978C (fr)
HK (2) HK1060726A1 (fr)
IL (1) IL156064A0 (fr)
MX (1) MXPA03005838A (fr)
NO (1) NO326014B1 (fr)
RU (1) RU2290403C2 (fr)
TW (1) TWI312779B (fr)
WO (1) WO2002053534A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
EP1499311B1 (fr) 2002-03-29 2009-11-04 Novartis Vaccines and Diagnostics, Inc. Benzazoles substituees et leur utilisation en tant qu'inhibiteurs de la kinase raf
ATE374768T1 (de) 2002-10-03 2007-10-15 Hoffmann La Roche Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
WO2004099136A1 (fr) * 2003-05-09 2004-11-18 Daiichi Pharmaceutical Co., Ltd. Procede de production de derives de pyrrolidine
EP1479675A1 (fr) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Derivés d'indazole en tant qu'inhibiteurs du facteur Xa
TWI340134B (en) 2003-07-24 2011-04-11 Daiichi Seiyaku Co Cyclohexanecarboxylic acids
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
US20070149606A1 (en) * 2003-12-26 2007-06-28 Daiichi Pharmaceutical Co.,Ltd. Process for producing phenylacetic acid derivative
WO2005066124A1 (fr) * 2003-12-26 2005-07-21 Daiichi Pharmaceutical Co., Ltd. Procede de production de derive de pyrrolidine
RU2393154C2 (ru) * 2004-03-24 2010-06-27 Йерини Аг Новые соединения для ингибирования ангиогенеза и их применение
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
TW200610754A (en) * 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (fr) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Procedes pour le traitement de l'hepatite c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275182A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating Hepatitis C
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体
WO2006068760A2 (fr) * 2004-11-19 2006-06-29 The Regents Of The University Of California Pyrazolopyrimidines anti-inflammatoires
RU2415846C2 (ru) * 2005-08-26 2011-04-10 Шионоги энд Ко., Лтд Производные, имеющие активность агонистов ppar-рецепторов
EP1961750B1 (fr) * 2005-12-13 2013-09-18 Daiichi Sankyo Company, Limited Médicament inhibiteur de vla-4
WO2008127226A2 (fr) * 2006-04-04 2008-10-23 The Regents Of The University Of California Antagonistes de kinase p13
DE102006021878A1 (de) * 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7858645B2 (en) * 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
WO2009046448A1 (fr) 2007-10-04 2009-04-09 Intellikine, Inc. Entités chimiques et leurs utilisations thérapeutiques
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101897881B1 (ko) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
JP5547099B2 (ja) * 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
CA2747252C (fr) 2008-12-19 2018-09-18 Vertex Pharmaceuticals Incorporated Derives pyrazines utiles en tant qu'inhibiteurs d'atr kinase
WO2010098866A1 (fr) 2009-02-27 2010-09-02 Supergen, Inc. Inhibiteurs cyclopentathiophène/cyclohexathiophène de l'adn méthyltransférase
CA2760791C (fr) 2009-05-07 2017-06-20 Intellikine, Inc. Composes heterocycliques et leurs utilisations
WO2010144550A1 (fr) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Dérivés de la triazine et leurs applications thérapeutiques
WO2010144394A1 (fr) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Dérivés de la triazine substituée au benzyle et leurs applications thérapeutiques
ES2557453T3 (es) 2009-06-09 2016-01-26 Nantbioscience, Inc. Derivados de isoquinolina, quinolina y quinazolina como inhibidores de la señalización de Hedgehog
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
WO2011047384A2 (fr) 2009-10-16 2011-04-21 The Regents Of The University Of California Procédés d'inhibition de l'activité ire1
WO2011056652A1 (fr) 2009-10-28 2011-05-12 Newlink Genetics Dérivés imidazole comme inhibiteurs de l'ido
WO2011146882A1 (fr) 2010-05-21 2011-11-24 Intellikine, Inc. Composés chimiques, compositions et procédés pour modulation de kinases
CA2817577A1 (fr) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Composes heterocycliques et utilisations de ceux-ci
KR101875720B1 (ko) 2011-01-10 2018-07-09 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
CN106619647A (zh) 2011-02-23 2017-05-10 因特利凯有限责任公司 激酶抑制剂的组合及其用途
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2900673A4 (fr) 2012-09-26 2016-10-19 Univ California Modulation de ire1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3052485B1 (fr) 2013-10-04 2021-07-28 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
EP4066834A1 (fr) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Composés hétérocycliques pour une utilisation dans le traitement de troubles à médiation pi3k-gamma
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016071499A1 (fr) * 2014-11-06 2016-05-12 Basf Se Composé hétérobicyclique de 3-pyridyle utilisé pour lutter contre les invertébrés nuisibles
PT3307734T (pt) 2015-06-09 2020-02-25 Abbvie Inc Moduladores de recetores nucleares (ror) para o tratamento de doenças inflamatórias e autoimunes
EP3350183A1 (fr) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Formes solides de dérivés d'isoquinolinone, leur procédé de fabrication, compositions les comprenant et méthodes d'utilisation de celles-ci
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP3873884A1 (fr) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Dérivés de quinoléine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
CA3114240C (fr) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Derives d'imidazopyridine utilises en tant qu'inhibiteurs de l'integrine alpha4beta7
WO2020092401A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOSÉS POUR INHIBITION DE L'INTÉGRINE ALPHA 4β7
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物
EP4165037A1 (fr) 2020-06-10 2023-04-19 Aligos Therapeutics, Inc. Composés antiviraux pour le traitement d'infections à coronavirus, picornavirus et norovirus
EP4284947A1 (fr) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Procedes d'évaluation du risque de développement d'une leuco-entéphalopathie multifocale progressive chez les patients traités par des antagonistes de la vla-4
KR20240035513A (ko) 2021-07-09 2024-03-15 알리고스 테라퓨틱스 인코포레이티드 항바이러스 화합물

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
DE2706977A1 (de) * 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
US4184658A (en) 1978-02-13 1980-01-22 General Electric Company Cushion mount for prime mover
DE3063878D1 (en) 1979-07-13 1983-07-28 Thomae Gmbh Dr K Derivatives of carboxylic acids, their preparation and medicaments containing them
JPS60181081A (ja) * 1984-02-29 1985-09-14 Kaken Pharmaceut Co Ltd 新規ビスベンゾフラニルケトン誘導体
JPH04112868A (ja) * 1990-09-03 1992-04-14 Otsuka Pharmaceut Co Ltd 置換ヘテロ環を有するフェニルカルボン酸誘導体
JPH0543574A (ja) 1991-08-13 1993-02-23 Wakamoto Pharmaceut Co Ltd ヘテロ環置換テトラゾール−１−酢酸誘導体
FR2694295B1 (fr) * 1992-07-28 1994-09-02 Adir Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent.
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
ES2103181B1 (es) 1994-08-01 1998-04-01 Menarini Lab Amidas naftalenicas con accion antagonista de los leucotrienos.
GB9408936D0 (en) 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
EP0835104A4 (fr) 1995-06-30 1999-10-20 Smithkline Beecham Corp Utilisation de composes se liant specifiquement au domaine stat 5 sh2 pour augmenter l'erythropoiese
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
CZ298089B6 (cs) 1996-07-25 2007-06-20 Biogen Idec Ma Inc. Inhibitory bunecné adheze, zpusob jejich prípravya farmaceutické prostredky s jejich obsahem
WO1998008818A1 (fr) 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibiteurs des enzymes phospholipases
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
HUP0000492A3 (en) * 1996-11-22 2000-06-28 Lilly Co Eli N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
US6117901A (en) 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
WO1999033789A1 (fr) 1997-12-23 1999-07-08 Aventis Pharma Limited β-ALANINES SUBSTITUEES
AU3297099A (en) * 1998-02-25 1999-09-15 Genetics Institute Inc. Inhibitors of phospholipase a2
PL198189B1 (pl) 1998-05-28 2008-06-30 Biogen Idec Ma (R)-N-{[4-{[(2-metylofenyloamino)-karbonylo]amino}fenylo]acetylo}-L-prolilo-3-metylo]-ß-alanina, jej zastosowanie i kompozycja farmaceutyczna ją zawierająca
CN1311771A (zh) * 1998-06-08 2001-09-05 味之素株式会社 苯甲脒衍生物
BR9911701A (pt) 1998-06-30 2001-03-20 Pfizer Prod Inc Inibidores não peptidila da ligação à célula dependente de vla-4 úteis no tratamento de doenças inflamatórias, auto-imunes e respiratórias
EP1133484A2 (fr) * 1998-07-23 2001-09-19 AstraZeneca AB Composes chimiques
GB9916374D0 (en) 1998-07-23 1999-09-15 Zeneca Ltd Chemical compounds
EP1114028B1 (fr) 1998-08-26 2006-11-29 Aventis Pharma Limited Bicycles aza modulant l'inhibition de l'adhesion cellulaire
GB9821199D0 (en) * 1998-09-30 1998-11-25 Glaxo Group Ltd Chemical compounds
US6207700B1 (en) 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
DE60027700T2 (de) 1999-02-16 2007-05-03 Aventis Pharma Ltd., West Malling Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
JP2000344666A (ja) 1999-04-01 2000-12-12 Sankyo Co Ltd 糖及び脂質代謝改善剤
ATE286896T1 (de) 1999-04-12 2005-01-15 Aventis Pharma Ltd Substituierte bicyclische heteroaryl-verbindungen als integrin antagonisten
JP2002543129A (ja) 1999-05-05 2002-12-17 メルク エンド カムパニー インコーポレーテッド 抗微生物剤としての新規なプロリン類
EP1177181B1 (fr) 1999-05-05 2009-01-28 Aventis Pharma Limited Composes bicycliques substitues
WO2000068195A2 (fr) 1999-05-05 2000-11-16 Aventis Pharma Limited Pyrrolidines substituees
DE60009480T2 (de) 1999-05-05 2005-09-01 Aventis Pharma Ltd., West Malling Harnstoffe als modulatoren der zelladhäsion
IL146288A0 (en) 1999-06-30 2002-07-25 Daiichi Seiyaku Co Vla-4 inhibitor compounds
US6756378B2 (en) * 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
JP2003506491A (ja) 1999-08-13 2003-02-18 バイオジェン インコーポレイテッド 細胞接着インヒビター
EP1263726B1 (fr) 1999-11-10 2007-09-26 Sanofi-Aventis Deutschland GmbH Derives de n-acylpyrrolidin-2-ylalkylbenzamidine utilises comme inhibiteurs du facteur xa
BR0016818A (pt) 1999-12-28 2002-10-01 Pfizer Prod Inc Inibidores não-peptidila de adesão celular dependente de vla-4 úteis no tratamento de doenças inflamatórias, auto-imunes e respiratórias
GB0001346D0 (en) 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
GB0004686D0 (en) 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
AU2001235806A1 (en) 2000-03-01 2001-09-12 Aventis Pharma Limited 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP4068452B2 (ja) 2000-07-19 2008-03-26 エフ．ホフマン−ラ ロシュ アーゲー エンドセリン変換酵素阻害剤としてのピロリジン誘導体
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists

Also Published As

Publication number Publication date
NO20032994D0 (no) 2003-06-27
HK1060726A1 (en) 2004-08-20
AU2002219555B2 (en) 2006-11-30
EP1346982A4 (fr) 2005-08-10
JPWO2002053534A1 (ja) 2004-04-30
NO326014B1 (no) 2008-09-01
AR035218A1 (es) 2004-05-05
HK1081545A1 (en) 2006-05-19
RU2290403C2 (ru) 2006-12-27
TWI312779B (fr) 2009-08-01
KR20030067730A (ko) 2003-08-14
CN1483024A (zh) 2004-03-17
NO20032994L (no) 2003-08-27
ATE524441T1 (de) 2011-09-15
BR0116608A (pt) 2004-06-29
MXPA03005838A (es) 2003-09-10
EP1346982A1 (fr) 2003-09-24
US20040110945A1 (en) 2004-06-10
US7157487B2 (en) 2007-01-02
CA2430978A1 (fr) 2002-07-11
WO2002053534A8 (fr) 2002-09-19
EP1346982B1 (fr) 2011-09-14
RU2003123115A (ru) 2005-03-27
CA2430978C (fr) 2012-05-15
KR100884877B1 (ko) 2009-02-23
CN100471838C (zh) 2009-03-25
JP4212358B2 (ja) 2009-01-21
WO2002053534A1 (fr) 2002-07-11

Similar Documents

Publication Publication Date Title
HK1081545A1 (en) Vla-4 inhibitors
AU2002219555A1 (en) VLA-4 Inhibitors
GB9900416D0 (en) Inhibitors
GB9912961D0 (en) Metalloprotease inhibitors
IL146288A0 (en) Vla-4 inhibitor compounds
PL356559A1 (en) 2-guanidino-4-arylchinazolines as nhe-3 inhibitors
IL145085A0 (en) Dihetero-substituted metalloprotease inhibitors
EP1153022A4 (fr) Inhibiteurs de protease
IL156212A0 (en) Farnesyltransferase inhibitors
EP1231921A4 (fr) Inhibiteurs de proteases
EP1229915A4 (fr) Inhibiteurs de protease
EP1229914A4 (fr) Inhibiteurs de protease
EP1229912A4 (fr) Inhibiteurs de protease
EP1161237A4 (fr) Inhibiteurs de protease
EP1173429A4 (fr) Inhibiteurs de protease
EP1229911A4 (fr) Inhibiteurs de proteases
GB2389113B (en) B-secretase inhibitor
GB0229613D0 (en) Biocatalyst inhibitors
GB0014861D0 (en) Novel telomerase inhibitors
GB0000829D0 (en) Growth inhibitor
GB0029730D0 (en) Inhibitors
GB0021193D0 (en) Inhibitors
GB0015996D0 (en) Inhibitors
GB0029733D0 (en) Inhibitors
GB0004895D0 (en) Inhibitor